Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
Analysts Have Conflicting Sentiments on These Healthcare Companies: Brookdale Senior Living (BKD), Regeneron (REGN) and Knight Therapeutics (OtherKHTRF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Brookdale Senior Living (BKD – Research Report), Regeneron (REGN – Research Report) and Knight Therapeutics (KHTRF...